Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI

Abstract

An attempt was made to compare the usefulness of determining markers carcinoembryonic antigen (CEA) and tumor-associated trypsin inhibitor (TATI) in endometrial cancer patients in whom recurrence or distant metastasis was diagnosed in observation after treatment. The study included 316 patients aged 32–81, average age of 61 years, SD = 8.72, with diagnosed endometrial cancer, treated between 1994 and 1995 at the Oncology Center in Warsaw and then under observation from 4 months to 17 years after completion of treatment. The levels of the markers TATI and CEA were assessed from the first five serum samples taken during postoperative radiotherapy and in the initial period of observation after completed treatment. Receiver operating characteristic (ROC) curves were generated, determining the sensitivity and specificity of both CEA and TATI in patients who experienced treatment failure, i.e., recurrence and distant metastasis. Assessing the sensitivity of the marker CEA, it was found that if in the third sample, i.e., during radiation therapy, the marker level increased by more than 20 % compared with the first sample, then recurrence of cancer occurred during the observation period in 75.9 % of patients and metastatic occurred in 69.7 % of patients. In the evaluation of the marker TATI, it was found that if the level of TATI between the first and the third sample increases by 10.6 % from the initial level, then in 84.4 % (sensitivity) of cases, this means the occurrence of cancer recurrence and in 75.7 % (sensitivity) of cases, the occurrence of metastasis. The specificity of both markers is low and not useful diagnostically.

Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status

“…However, we observed that elevated S-TATI appears to function as an independent prognostic biomarker in OPSCC ( Table 2 ). Similar results were observed in other malignancies [ 28 , 39 , 40 ].…”

CA 125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding

“…However, elevated levels of CEA are reported in many carcinomas of epithelial origin like, lung adenocarcinoma, ovarian carcinoma and endometrial adenocarcinoma24. Kozakiewicz B et al showed that elevated CEA levels were not sensitive and specific enough to diagnose and monitor treatment of endometrial cancer25.…”

Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma

“…S-TATI seems to predict survival in several cancers [7,[14][15][16]. An increase in S-TATI levels after radically intended surgery of ovarian cancer predicts the recurrence and occurrence of metastases [16].…”

“…S-TATI seems to predict survival in several cancers [7,[14][15][16]. An increase in S-TATI levels after radically intended surgery of ovarian cancer predicts the recurrence and occurrence of metastases [16]. A recent study by Peltonen et al [15] reported that S-TATI, taken at 3 months after resection of liver metastasis of colorectal carcinoma, was not associated with shorter disease-free survival or overall survival (OS).…”